

Expert Consultation
on the
Use of Placebos in Vaccine Trials



World Health
Organization

WHO Library Cataloguing-in-Publication Data

Expert consultation on the use of placebos in vaccine trials.

1.Vaccines – standards. 2.Placebos – therapeutic use. 3.Clinical trial 4.Ethics.
5.Communicable diseases. I.World Health Organization.

ISBN 978 92 4 150625 0

(NLM classification: QW 805)

© **World Health Organization 2013**

All rights reserved. Publications of the World Health Organization are available on [the WHO web site \(www.who.int\)](http://www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be [addressed to WHO Press through the WHO web site \(www.who.int/about/licensing/copyright_form/en/index.html\)](http://www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in (Geneva, Switzerland)

Expert Consultation
on the
Use of Placebos in Vaccine Trials



**World Health
Organization**

Table of Contents

| | |
|--|-----------|
| Acknowledgments | 07 |
| Abbreviations | 08 |
| Background | 09 |
| Introduction | 11 |
| Overarching Research Ethics Principles | |
| Ethical Considerations relevant to the General Use of Placebos | |
| Ethical Considerations for the Use of Placebos in Vaccine Research | |
| Acceptability of Use of Placebos | 15 |
| Five Situations where Placebos may be Acceptable | |
| Recommendations | 19 |
| Procedural Recommendations | |
| Substantive Recommendations | |
| Conclusion | 22 |
| Annex 1: List of Participants | |
| Annex 2: Selected Guidance and Regulations on the Use of Placebos in Clinical Research | |
| Annex 3: Alternative Trial Designs in lieu of Individually Randomized Controlled Trials (including Placebo-Controlled Trials) | |
| Box 1: HIV Vaccine Trials in Thailand | |
| Box 2: CIOMS (2002) International Ethical Guidelines for Biomedical Research | |
| Box 3: Control Vaccines | |
| Box 4: Pneumococcal Vaccine Trial in Bangladesh | |
| Box 5: Rotavirus Vaccine Trials in India | |

Acknowledgments

The Expert Consultation on the Use of Placebos in Vaccine Trials was convened by the World Health Organization (WHO) in Annecy, France on 17–18 January 2013 under the overall guidance of Rüdiger Krech, WHO Director of the Department of Ethics and Social Determinants, and Marie-Paule Kieny, Assistant Director-General, Health Systems and Innovation. WHO is grateful to the panel of experts who contributed to this Report (see Annex 1).

Special thanks go to James Colgrove and Annette Rid for acting as rapporteurs, and to James Colgrove for developing the first draft of this report.

The following experts' contributions to the case studies described in the document are also acknowledged: Ames Dhai, Pieter Neels, Punnee Pitisuttithum, Michael Selgelid and Mark Sheehan.

The input of Patricia Loh, working as an intern with the WHO Department of Ethics and Social Determinants, is particularly appreciated for her dedication to ensuring that all the comments and recommendations of the experts are included and that the document is consistent and concise.

Finally, gratitude is expressed to the following WHO staff members for their valuable comments and support: Marie-Charlotte Bouesseau, Sergio Nishioka, Vaseeharan Sathiyamoorthy, and Abha Saxena.

Abbreviations

| | |
|-----------------|--|
| CIOMS | Council for International Organizations of Medical Sciences |
| HIC | high-income country |
| HIV/AIDS | human immunodeficiency virus / acquired immunodeficiency syndrome |
| ICH | International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use |
| LMIC | low- and middle-income countries |
| REC | research ethics committee |
| UNAIDS | Joint United Nations Programme on HIV/AIDS |
| WHO | World Health Organization |
| WMA | World Medical Association |

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28214

